Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
BioConferenceLive

A Mitochondrial Transport Protein Protects Cancer Cells from Toxic Nanoparticles

By BiotechDaily International staff writers
Posted on 06 Jun 2013
Image: Senior author Dr. Priyabrata Mukherjee (Photo courtesy of the Mayo Clinic).
Image: Senior author Dr. Priyabrata Mukherjee (Photo courtesy of the Mayo Clinic).
A recent paper stressed the importance of linking the use of anticancer nanoparticle drugs and drug carriers to a basic understanding of the role of the mitochondria in the apoptotic process.

Cancer cells are surprisingly resistant to toxic effects of positively charged gold nanoparticles (+AuNPs). Investigators at the Mayo Clinic (Rochester, MN, USA) examined the interaction of +AuNPs with ovarian cancer cells growing in culture in order to determine the molecular mechanism protecting the cancer cells from the nanoparticles.

They reported in the April 24, 2013, online edition of the Journal of Biological Chemistry that the protein MICU1, a mitochondrial calcium uniporter, as a key molecule conferring cancer cells with resistance to +AuNPs. A uniporter is an integral membrane protein, either a channel or a carrier protein that is involved in facilitated diffusion. Uniporter carrier proteins work by binding to one molecule of solute at a time and transporting it with the solute gradient.

The MICU1 (mitochondrial calcium uptake 1) gene encodes an essential regulator of mitochondrial Ca2+ uptake under basal conditions. The encoded protein interacts with the mitochondrial calcium uniporter, a mitochondrial inner membrane Ca2+ channel, and is essential in preventing mitochondrial Ca2+ overload, which can cause excessive production of reactive oxygen species and cell stress.

The investigators found that in the ovarian cancer cells the increase in cytosolic Ca2+ induced by +AuNPs was balanced by MICU1, which prevented cell death. Silencing MICU1 decreased Bcl-2 (B-cell lymphoma 2), expression and increased caspase-3 activity and cytosolic cytochrome C levels—effects further enhanced in the presence of +AuNPs—thus initiating the mitochondrial pathway for apoptosis.

"This study identifies a novel mechanism that protects ovarian cancer cells by preventing the cell death, or apoptosis, which should occur when they encounter positively charged nanoparticles," said senior author Dr. Priyabrata Mukherjee, associate professor of biomedical engineering at the Mayo Clinic. "Furthermore, this work establishes MICU1 as a novel regulator of the apoptotic machinery in cancer cells and emphasizes the need to synergize nanoparticle design with understanding of mitochondrial machinery for enhancing targeted cellular toxicity."


Related Links:

Mayo Clinic



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Therapeutics

view channel

Vaccine Being Developed for Heart Disease Close to Reality

The world’s first vaccine for heart disease is becoming a possibility with researchers demonstrating significant arterial plaque reduction in concept testing in mice. Klaus Ley, MD, from the La Jolla Institute for Allergy and Immunology (LA Jolla, CA, USA), and a vascular immunology specialist, is leading the vaccine... Read more

Business

view channel

A Surge in IPOs Revitalize Investments for the Global Pharma and Biotech

Anti-infective drugs, oncology, and pharmaceutical contract laboratories attract the most investment up to now. The intensified private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008–2010, witnessed a waning post-2010. However, the decline in deals... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.